Related Experiment Video
Updated: Apr 30, 2026

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
Lipid-based carriers for pulmonary products: preclinical development and case studies in humans
David Cipolla1, Boris Shekunov2, Jim Blanchard1
1Aradigm Corporation, 3929 Point Eden Way, Hayward, CA 94545, USA.
Abstract:
A number of lipid-based technologies have been applied to pharmaceuticals to modify their drug release characteristics, and additionally, to improve the drug loading for poorly soluble drugs. These technologies, including solid-state lipid microparticles, many of which are porous in nature, liposomes, solid lipid nanoparticles and nanostructured lipid carriers, are increasingly being developed for inhalation applications. This article provides a review of the rationale for the use of these technologies in the pulmonary delivery of drugs, and summarizes the manufacturing processes and their limitations, the in vitro and in vivo performance of these systems, the safety of these lipid-based systems in the lung, and their promise for commercialization.
Related Concept Videos
Preclinical Development: Overview
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Bioavailability Enhancement: Drug Permeability Enhancement
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Carrier-Mediated Transport
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Modified-Release Drug Delivery Systems: Influencing Factors

